Yesterday, a Director at Zoetis (ZTS), Willie Reed, sold shares of ZTS for $210.1K.
Following Willie Reed’s last ZTS Sell transaction on December 03, 2018, the stock climbed by 17.6%. In addition to Willie Reed, 4 other ZTS executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Zoetis’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $1.46 billion and quarterly net profit of $312 million. In comparison, last year the company earned revenue of $1.37 billion and had a net profit of $352 million. ZTS’s market cap is $53.07B and the company has a P/E ratio of 38.71. The Company has a Price to Book ratio of 22.9093.
Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $115.20, reflecting a 4.0% upside.
The insider sentiment on Zoetis has been negative according to 57 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.
